bioAffinity Technologies Inc. Common Stock BIAF · Stock Open bioAffinity Technologies Inc. Common Stock in new tab
bioAffinity Technologies Inc. Common Stock Analysis (BIAF)
Is bioAffinity Technologies Inc. Common Stock a good investment? bioAffinity Technologies Inc. Common Stock (BIAF) is currently trading at 6.15 USD.
Earnings Schedule: bioAffinity Technologies Inc. Common Stock is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is -0.60.
Investor FAQ
Does bioAffinity Technologies Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is bioAffinity Technologies Inc. Common Stock?
bioAffinity Technologies Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -1.35.
Company Profile
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 19, 2025 | 0.03 |
| Aug. 24, 2026 | Needs review |
Community Discussion